Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michael R Migden"'
Autor:
Reinhard Dummer, Aaron S. Farberg, Michael R. Migden, Alexander Guminski, Karl D. Lewis, Nicholas Squittieri
Publikováno v:
Dermatology and Therapy
Introduction Sonidegib is a Hedgehog pathway inhibitor approved to treat locally advanced basal cell carcinoma and, depending on regulatory approval, metastatic basal cell carcinoma. Results from the BOLT study demonstrated robust efficacy and contin
Autor:
Matthew G. Fury, Siyu Li, Medha Sasane, Dirk Schadendorf, Nikhil I. Khushalani, Karl D. Lewis, Vera Mastey, Elizabeth Stankevich, Axel Hauschild, Jocelyn Booth, Michael R. Migden, Anne Lynn S. Chang, Suk Young Yoo, Chieh I. Chen, Leonel Hernandez-Aya, Emmanuel Okoye, Zhen Chen, Chrysalyne D. Schmults, Israel Lowy, Alexander Guminski, Brett G.M. Hughes, Danny Rischin, Alesha A. Thai, Annette M. Lim
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
BackgroundTo provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to determine duration of response (DOR) and impact on quality of life (QoL).Method
Autor:
R. Ferrarotto, Jason M. Johnson, Randal S. Weber, Diana Bell, M. Wong, Neil D. Gross, J.N. Myers, Bonnie S. Glisson, Bita Esmaeli, Ying Yuan, Priyadharsini Nagarajan, Michael R. Migden, David I. Rosenthal, Adel K. El-Naggar, Jennifer A. Wargo
Publikováno v:
Annals of Oncology. 30:v910
Background Cutaneous squamous cell carcinoma (CSCC) harbors a high tumor mutation burden (TMB) due to ultraviolet light-mediated DNA damage, and are highly immune-responsive. Cemiplimab, a monoclonal antibody directed against programmed death 1 (PD-1
Autor:
H.-J. Schulze, R. Herd, Carmen Loquai, Frank Cornelis, Ragini R. Kudchadkar, Karl D. Lewis, Martin Kaatz, Dalila Sellami, Reinhard Dummer, Anne Lynn S. Chang, Patrick Combemale, Alexander Guminski, John T. Lear, Ralf Gutzmer, Tingting Yi, Luc Dirix, Uwe Trefzer, Ruth Plummer, Michael R. Migden, Alexandros Stratigos
Publikováno v:
Annals of Oncology. 25:v1
Aim: The BOLT phase 2 study, comparing 2 doses of sonidegib, a hedgehog pathway inhibitor (HhPI), in pts with advanced BCC (aBCC; NCT01327053), met its primary endpoint of objective response rate ≥30% in both arms in analyses of data collected up t